摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,8-二氯查尔酮-2-羧酸 | 16722-38-6

中文名称
6,8-二氯查尔酮-2-羧酸
中文别名
——
英文名称
6,8-dichloro-4-oxochromene-2-carboxylic acid
英文别名
6,8-Dichlorochromone-2-carboxylic acid
6,8-二氯查尔酮-2-羧酸化学式
CAS
16722-38-6
化学式
C10H4Cl2O4
mdl
——
分子量
259.045
InChiKey
FSTRRPXNRFANIZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    428.2±45.0 °C(Predicted)
  • 密度:
    1.712±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2932999099

SDS

SDS:6cfb28be9c937c9696bcafa9259c8607
查看

反应信息

  • 作为反应物:
    描述:
    6,8-二氯查尔酮-2-羧酸三溴化硼caesium carbonateN,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 30.0h, 生成 methyl 4-(5-chloro-2-(6,8-dichloro-4-oxochromene-2-carboxamido)phenoxy)butanoate
    参考文献:
    名称:
    [EN] CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE
    [FR] DÉRIVÉS DE CHROMEN-4-ONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE MALADIE DUE AU VIRUS DE L'HÉPATITE B
    摘要:
    本发明提供了具有通式(I)的新化合物,其中R1至R6和m如本文所述,包括该化合物的组合物以及使用该化合物的方法。
    公开号:
    WO2020079106A1
  • 作为产物:
    描述:
    3',5'-二氯-2'-羟基苯乙酮草酸二乙酯sodium ethanolate盐酸溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 17.0h, 以50%的产率得到6,8-二氯查尔酮-2-羧酸
    参考文献:
    名称:
    [EN] CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE
    [FR] DÉRIVÉS DE CHROMEN-4-ONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE MALADIE DUE AU VIRUS DE L'HÉPATITE B
    摘要:
    本发明提供了具有通式(I)的新化合物,其中R1至R6和m如本文所述,包括该化合物的组合物以及使用该化合物的方法。
    公开号:
    WO2020079106A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] CYCLOLALKYLES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA VOIE DE STRESS INTÉGRÉE
    申请人:CALICO LIFE SCIENCES LLC
    公开号:WO2020223536A1
    公开(公告)日:2020-11-05
    Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    本文提供了用于调节综合应激反应(ISR)并治疗相关疾病、疾病和症状的化合物、组合物和方法。
  • [EN] SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] DERIVES DE PIPERIDINE ET DE PIPERAZINE SUBSTITUES UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA MELANOCORTINE-4
    申请人:MYOCONTRACT LTD
    公开号:WO2004083208A1
    公开(公告)日:2004-09-30
    The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.
    本发明涉及一种新型的替代哌啶和哌嗪衍生物,作为黑色素皮质素-4受体(MC-4R)调节剂。本发明的MC-4R激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病,而MC-4R拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。所有涉及MC-4R调节的疾病和障碍均可使用本发明的化合物治疗。
  • [EN] SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] DERIVES A SUBSTITUTION PIPERIDINE ET PIPERAZINE AGISSANT COMME MODULATEURS DU RECEPTEUR DE LA MELANOCORTINE 4
    申请人:MYOCONTRACT LTD
    公开号:WO2004083199A1
    公开(公告)日:2004-09-30
    The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
    本发明涉及一种新型的取代哌啶和哌嗪衍生物,作为黑色素皮质素-4受体(MC-4R)调节剂。本发明中的MC-4R激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病,而MC-4R拮抗剂则可用于治疗癌症恶病质、肌肉萎缩、厌食、焦虑和抑郁等疾病和疾病。所有涉及MC-4R调节的疾病和疾病都可以用本发明中的化合物进行治疗。
  • Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators
    申请人:Soeberdt Michael
    公开号:US20070155783A1
    公开(公告)日:2007-07-05
    The present invention relates to novel substituted cyclohexyl and piperidinyl derivatives as melanocortin-4. receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
    本发明涉及一种新型的取代环己基和哌啶基衍生物,作为黑色素皮质素-4受体(MC-4R)调节剂。本发明中的MC-4R激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病,而MC-4R拮抗剂则可用于治疗癌症消瘦、肌肉消耗、厌食、焦虑和抑郁等疾病和疾病。所有涉及MC-4R调节的疾病和疾病均可使用本发明中的化合物进行治疗。
  • Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
    申请人:Soeberdt Michael
    公开号:US20070037823A1
    公开(公告)日:2007-02-15
    The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.
    本发明涉及一种新的取代哌啶和哌嗪衍生物,作为黑色素皮质激素-4受体(MC-4R)调节剂。本发明的MC-4R激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病,而MC-4R拮抗剂则可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁症等疾病和疾病。所有涉及MC-4R调节的疾病和疾病都可以用本发明的化合物治疗。
查看更多